Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1148 | 995 | 1242 | 1285 | 1570 | 2156 |
Fund Return | 14.77% | -0.46% | 24.17% | 8.72% | 9.44% | 7.99% |
Place in category | 20 | 229 | 113 | 22 | 70 | 75 |
% in Category | 2 | 11 | 6 | 1 | 4 | 5 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
JPM Global Income A acc EUR | 17.93B | 6.41 | -0.68 | 2.08 | ||
LU0740858492 | 17.93B | 6.10 | -1.03 | 1.72 | ||
JPMorgan Global Income A Div EUR | 17.93B | 6.41 | -0.68 | 2.08 | ||
JPM Global Income Fund A Mth EUR | 17.93B | 6.40 | -0.69 | - | ||
JPMorgan Global Income D div EUR | 17.93B | 6.10 | -1.03 | 1.73 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
European Growth Fund A Acc EUR | 160.17M | 12.55 | 4.13 | 5.59 | ||
European Growth Fund E Acc EUR | 21.05M | 11.84 | 3.35 | 4.80 | ||
European Growth Fund Y Acc EUR | 200.52M | 13.30 | 5.02 | 6.46 | ||
European Growth Fund Y DIST EUR | 65.13M | 13.33 | 5.02 | 6.47 | ||
European Growth Fund A DIST Eue | 6.63B | 12.54 | 4.13 | 5.59 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
JPMorgan Liquidity Funds Euro Liquidity Fund X ( | LU0836346931 | 4.47 | 10,533.850 | +0.01% | |
Novo Nordisk B | DK0062498333 | 3.76 | 750.9 | +4.03% | |
ASML Holding | NL0010273215 | 3.15 | 642.10 | +1.68% | |
Novartis | CH0012005267 | 2.99 | 93.68 | +2.32% | |
SAP | DE0007164600 | 2.71 | 225.900 | +0.53% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review